Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, a clinical-stage biopharmaceutical firm, announced its Q1 2024 results. The company reported a net loss of $7.4 million, or $0.16 per share, an improvement from $0.32 per share in the same period last year. Forte's cash reserves stood at $30.4 million by the end of the quarter. R&D expenses dropped to $4.4 million from $4.8 million YoY, while G&A expenses rose to $3.5 million from $2.1 million. The company's phase 1 trial for its drug candidate FB102 has shown a good safety profile, with completion of multiple ascending dose cohorts expected mid-year. Forte plans to start patient-based studies by year-end, aiming to address various autoimmune diseases.
- Net loss per share improved from $0.32 to $0.16 YoY.
- R&D expenses decreased from $4.8 million to $4.4 million YoY.
- FB102 phase 1 trial showed a good safety profile.
- Completion of multiple ascending dose cohorts expected mid-year.
- Plans to initiate patient-based studies by year-end.
- Net loss increased to $7.4 million from $6.7 million YoY.
- Cash and cash equivalents decreased from $37.1 million to $30.4 million.
- G&A expenses rose significantly from $2.1 million to $3.5 million YoY.
- Total assets decreased from $39 million to $32 million YoY.
Insights
Forte Biosciences reported a
On the other hand, general and administrative (G&A) expenses jumped to
Forte completed the quarter with
Net losses per share improved to (
Forte Biosciences' advancements with their lead candidate FB102 are noteworthy. The company has completed the single ascending dose (SAD) portion of their Phase 1 trial and is progressing into the multiple ascending dose (MAD) cohorts. The early data showing a good safety profile is promising, especially for a drug targeting autoimmune and autoimmune-related diseases. Safety in early trials is a critical milestone, as it can significantly de-risk the program moving forward.
Initiating patient-based studies later this year will be a pivotal step. These studies will provide deeper insights into the drug's efficacy and potential market impact. The reference to large addressable markets suggests that FB102 could address significant unmet medical needs, which is a positive indicator for future revenue streams if clinical trials prove successful.
Investors should watch for upcoming data releases on the MAD cohorts and initial patient studies, as these will be important in validating the drug’s therapeutic potential and positioning within the competitive landscape of autoimmune disease treatments.
First Quarter 2024 Business Highlights
“Forte continues to make excellent progress with FB102. As we indicated last quarter, the single ascending dose (SAD) portion of the FB102 phase 1 trial was successfully completed. We expect the dosing of the multiple ascending dose (MAD) cohorts of the phase 1 trial in the healthy volunteers to complete around mid-year. To date, FB102 has demonstrated a good safety profile, including in the MAD cohorts,” said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. “We look forward to initiating patient-based studies before the end of the year. We believe the data to date supports the significant potential for FB102 across a variety of autoimmune and autoimmune-related diseases with large addressable markets and we look forward to addressing these opportunities as we continue to advance the FB102 program.”
First Quarter 2024 Operating Results
Research and development expenses were
General and administrative expenses were
Net losses per share were (
Forte ended the first quarter 2024 with approximately
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands except share and par value data) |
||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ |
30,444 |
|
$ |
37,125 |
|
||
| Prepaid expenses and other current assets |
|
1,058 |
|
|
1,202 |
|
||
| Total current assets |
|
31,502 |
|
|
38,327 |
|
||
| Property and equipment, net |
|
106 |
|
|
109 |
|
||
| Other assets |
|
409 |
|
|
544 |
|
||
| Total assets | $ |
32,017 |
|
$ |
38,980 |
|
||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ |
1,685 |
|
$ |
1,424 |
|
||
| Accrued liabilities |
|
1,647 |
|
|
2,242 |
|
||
| Total current liabilities |
|
3,332 |
|
|
3,666 |
|
||
| Commitments and contingencies (Note 6) | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, |
|
36 |
|
|
36 |
|
||
| Additional paid-in capital |
|
154,591 |
|
|
153,794 |
|
||
| Accumulated other comprehensive income (loss) |
|
(2 |
) |
|
4 |
|
||
| Accumulated deficit |
|
(125,940 |
) |
|
(118,520 |
) |
||
| Total stockholders’ equity |
|
28,685 |
|
|
35,314 |
|
||
| Total liabilities and stockholders’ equity | $ |
32,017 |
|
$ |
38,980 |
|
||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
||||||||
(in thousands, except share and per share amounts) |
||||||||
| For the Three Months Ended March 31, | ||||||||
|
2024 |
|
|
2023 |
|
|||
| Operating expenses: | ||||||||
| Research and development (including |
$ |
4,353 |
|
$ |
4,787 |
|
||
| General and administrative |
|
3,451 |
|
|
2,068 |
|
||
| Total operating expenses |
|
7,804 |
|
|
6,855 |
|
||
| Loss from operations |
|
(7,804 |
) |
|
(6,855 |
) |
||
| Other income, net |
|
384 |
|
|
102 |
|
||
| Net loss | $ |
(7,420 |
) |
$ |
(6,753 |
) |
||
| Per share information: | ||||||||
| Net loss per share - basic and diluted | $ |
(0.16 |
) |
$ |
(0.32 |
) |
||
| Weighted average shares and pre-funded warrants outstanding, basic and diluted |
|
46,082,861 |
|
|
21,006,680 |
|
||
| Comprehensive Loss: | ||||||||
| Net loss | $ |
(7,420 |
) |
$ |
(6,753 |
) |
||
| Unrealized loss on available-for-sale securities |
|
(6 |
) |
|
— |
|
||
| Comprehensive loss | $ |
(7,426 |
) |
$ |
(6,753 |
) |
||
Additional details on our first quarter 2024 financial results can be found in Forte’s Form 10-Q as filed with the SEC on May 13, 2024. You can also find more information in the investor relations section of our website at www.fortebiorx.com.
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing its product candidate, FB102, which is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications including in such indications as graft-versus-host disease, vitiligo and alopecia areata.
Forward-Looking Statements
Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward-looking statements include statements regarding the Company’s beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte’s ability to obtain sufficient additional capital to continue to advance Forte’s product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte’s product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials, including the timing of the commencement of the Company’s patient-based studies; the risk that results from preclinical and any interim result of our ongoing phase 1 clinical trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte’s business and operating results is contained in Forte’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 18, 2024, in the Company’s subsequent Quarterly Report on Form 10-Q filed on May 13, 2024 and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513927812/en/
LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com
Source: Forte Biosciences, Inc.
FAQ
What were Forte Biosciences' net losses in Q1 2024?
How much has Forte Biosciences' net loss per share improved in Q1 2024 compared to Q1 2023?
What were Forte Biosciences' cash reserves at the end of Q1 2024?
How did Forte Biosciences' R&D expenses change in Q1 2024?
What was the increase in Forte Biosciences' G&A expenses in Q1 2024?
What is the status of Forte Biosciences' FB102 phase 1 trial?
When does Forte Biosciences plan to start patient-based studies for FB102?
